Announced Date: 2024-01-07 (January 7, 2024)
Asset Name: Two RNAi programs (RNA interference)
Licensor: Argo (Shanghai Argo Biopharmaceutical Co., Ltd. , China)
Licensee (Buyer): Novartis (Novartis Pharma AG)
.
Scope of Authority:
Under the first agreement, Argo has granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. The first agreement also includes a research collaboration and Novartis also receives an option to potentially license compounds directed against up to two additional targets for cardiovascular disease treatment.
.
Under the second agreement, Argo granted Novartis an exclusive ex-Greater China license to develop and commercialize a Phase 1/2a clinical-stage program for cardiovascular disease treatment.
.
Payment Detail:
Upfront payment of $185 million,
Total up to $4.165 billion.
And tiered royalties.
.
Link:
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
